190 related articles for article (PubMed ID: 36655671)
1. [A precision medication study of atomoxetine in children with attention deficit hyperactivity disorder:
Fu D; Guo HL; Hu YH; Chen F
Zhongguo Dang Dai Er Ke Za Zhi; 2023 Jan; 25(1):98-103. PubMed ID: 36655671
[TBL] [Abstract][Full Text] [Related]
2. Individualized atomoxetine response and tolerability in children with ADHD receiving different dosage regimens: the need for CYP2D6 genotyping and therapeutic drug monitoring to dance together.
Guo HL; Wu DD; Fu D; Li Y; Wang J; Zhang YY; Wang WJ; Huang J; Fang WR; Xu J; Hu YH; Liu QQ; Chen F
Transl Psychiatry; 2024 Mar; 14(1):151. PubMed ID: 38504095
[TBL] [Abstract][Full Text] [Related]
3. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
Garnock-Jones KP; Keating GM
Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
[TBL] [Abstract][Full Text] [Related]
4. Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy.
Brown JT; Bishop JR; Sangkuhl K; Nurmi EL; Mueller DJ; Dinh JC; Gaedigk A; Klein TE; Caudle KE; McCracken JT; de Leon J; Leeder JS
Clin Pharmacol Ther; 2019 Jul; 106(1):94-102. PubMed ID: 30801677
[TBL] [Abstract][Full Text] [Related]
5. A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD).
Ramoz N; Boni C; Downing AM; Close SL; Peters SL; Prokop AM; Allen AJ; Hamon M; Purper-Ouakil D; Gorwood P
Neuropsychopharmacology; 2009 Aug; 34(9):2135-42. PubMed ID: 19387424
[TBL] [Abstract][Full Text] [Related]
6. Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability.
Brown JT; Bishop JR
Pharmacogenomics; 2015; 16(13):1513-20. PubMed ID: 26314574
[TBL] [Abstract][Full Text] [Related]
7. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD.
Michelson D; Read HA; Ruff DD; Witcher J; Zhang S; McCracken J
J Am Acad Child Adolesc Psychiatry; 2007 Feb; 46(2):242-51. PubMed ID: 17242628
[TBL] [Abstract][Full Text] [Related]
8. CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial.
Fijal BA; Guo Y; Li SG; Ahl J; Goto T; Tanaka Y; Nisenbaum LK; Upadhyaya HP
J Clin Pharmacol; 2015 Oct; 55(10):1167-74. PubMed ID: 25919121
[TBL] [Abstract][Full Text] [Related]
9. A systematic review of the use of atomoxetine for management of comorbid anxiety disorders in children and adolescents with attention-deficit hyperactivity disorder.
Khoodoruth MAS; Ouanes S; Khan YS
Res Dev Disabil; 2022 Sep; 128():104275. PubMed ID: 35691145
[TBL] [Abstract][Full Text] [Related]
10. Personalizing atomoxetine dosing in children with ADHD: what can we learn from current supporting evidence.
Fu D; Guo HL; Hu YH; Fang WR; Liu QQ; Xu J; Wu DD; Chen F
Eur J Clin Pharmacol; 2023 Mar; 79(3):349-370. PubMed ID: 36645468
[TBL] [Abstract][Full Text] [Related]
11. [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].
Purper-Ouakil D; Fourneret P; Wohl M; Rénéric JP
Encephale; 2005; 31(3):337-48. PubMed ID: 16142049
[TBL] [Abstract][Full Text] [Related]
12. Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition.
Yu G; Li GF; Markowitz JS
J Child Adolesc Psychopharmacol; 2016 May; 26(4):314-26. PubMed ID: 26859445
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with atomoxetine efficacy for treatment of attention-deficit/hyperactivity disorder in children and adolescents.
Scott NG; Ripperger-Suhler J; Rajab MH; Kjar D
J Child Adolesc Psychopharmacol; 2010 Jun; 20(3):197-203. PubMed ID: 20578932
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic drug monitoring of atomoxetine in children and adolescents with attention-deficit/ hyperactivity disorder: a naturalistic study.
Ruppert K; Geffert C; Clement HW; Bachmann C; Haberhausen M; Schulz E; Fleischhaker C; Biscaldi-Schäfer M
J Neural Transm (Vienna); 2022 Jul; 129(7):945-959. PubMed ID: 35391568
[TBL] [Abstract][Full Text] [Related]
15. The Pharmacogenetic Impact on the Pharmacokinetics of ADHD Medications.
Brown JT
Methods Mol Biol; 2022; 2547():427-436. PubMed ID: 36068472
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics of atomoxetine.
Sauer JM; Ring BJ; Witcher JW
Clin Pharmacokinet; 2005; 44(6):571-90. PubMed ID: 15910008
[TBL] [Abstract][Full Text] [Related]
17. A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain.
Hong J; Dilla T; Arellano J
BMC Psychiatry; 2009 Apr; 9():15. PubMed ID: 19366449
[TBL] [Abstract][Full Text] [Related]
18. The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research.
Reed VA; Buitelaar JK; Anand E; Day KA; Treuer T; Upadhyaya HP; Coghill DR; Kryzhanovskaya LA; Savill NC
CNS Drugs; 2016 Jul; 30(7):603-28. PubMed ID: 27290715
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetic Analysis of Atomoxetine and its Metabolites in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
Cheng S; Al-Kofahi M; Leeder JS; Brown JT
Clin Pharmacol Ther; 2024 May; 115(5):1033-1043. PubMed ID: 38117180
[TBL] [Abstract][Full Text] [Related]
20. A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability.
Treuer T; Gau SS; Méndez L; Montgomery W; Monk JA; Altin M; Wu S; Lin CC; Dueñas HJ
J Child Adolesc Psychopharmacol; 2013 Apr; 23(3):179-93. PubMed ID: 23560600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
